Microparticle surface modifications targeting dendritic cells for non-activating applications

Biomaterials

Volumn 33, Issue 29, 2012, Pages 7221-7232

  Lewis, Jamal S ^a   Zaveri, Toral D ^a   Crooks, Charles P ^a   Keselowsky, Benjamin G ^a  

^a University of Florida   (United States)

Author keywords

Dendritic cell; Microparticle; Microsphere; Non activating; Phagocytosis; Vaccine

Indexed keywords

ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; C-TYPE LECTINS; DELIVERY SYSTEMS; DENDRITIC CELLS; FUNCTIONALIZATIONS; IN-VITRO; IN-VIVO; INTEGRINS; MICRO PARTICLES; MICROPARTICLE SURFACES; MICROPARTICULATE SYSTEM; NON-ACTIVATING; PHAGOCYTOSIS; RECEPTOR TARGETING; RGD PEPTIDE; TIME POINTS;

ANTIGEN-ANTIBODY REACTIONS; CELLS; MICROSPHERES; PEPTIDES; VACCINES;

ANTIBODIES;

ARGINYLGLYCYLASPARTIC ACID; B7 ANTIGEN; CD86 ANTIGEN; FLUORESCENT DYE; GLYCOPROTEIN P 15095; INTEGRIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE RECEPTOR; PEPTIDE; POLYGLACTIN; RECEPTOR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL MATURATION; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DENDRITIC CELL; FEMALE; IMMUNOTHERAPY; LYMPH NODE; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN MODIFICATION; TRANSPLANTATION TOLERANCE; ZETA POTENTIAL;

ANIMALS; ANTIGENS, CD11C; CYTOKINES; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY; LACTIC ACID; LIGANDS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICROSPHERES; PEPTIDES; PHAGOCYTOSIS; POLYGLYCOLIC ACID; PROTEIN BINDING; SURFACE PROPERTIES; VACCINES;

EID: 84864297173     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.06.049     Document Type: Article

References (61)

1. Jiang W., Gupta R.K., Deshpande M.C., Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005, 57(3):391-410.
2. Ohagan D.T., Rahman D., Mcgee J.P., Jeffery H., Davies M.C., Williams P., et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 1991, 73(2):239-242.
3. Jaganathan K.S., Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 2006, 24(19):4201-4211.
4. Rajapaksa T.E., Lo D.D. Microencapsulation of vaccine antigens and adjuvants for mucosal targeting. Cur Immunol Rev 2010, 6(1):29-37.
5. Perez C., Sanchez A., Putnam D., Ting D., Langer R., Alonso M.J. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release 2001, 75(1-2):211-224.
6. Tinsley-Bown A.M., Fretwell R., Dowsett A.B., Davis S.L., Farrar G.H. Formulation of poly(d, l-lactic-co-glycolic acid) microparticles for rapid plasmid DNA delivery. J Control Release 2000, 66(2-3):229-241.
7. Walter E., Moelling K., Pavlovic J., Merkle H.P. Microencapsulation of DNA using poly(dl-lactide-co-glycolide): stability issues and release characteristics. J Control Release 1999, 61(3):361-374.
8. Mohammadi G., Valizadeh H., Barzegar-Jalali M., Lotfipour F., Adibkia K., Milani M., et al. Development of azithromycin-PLGA nanoparticles: physicochemical characterization and antibacterial effect against Salmonella typhi. Colloids Surf B 2010, 80(1):34-39.
9. Acharya A.P., Clare-Salzler M.J., Keselowsky B.G. A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines. Biomaterials 2009, 30(25):4168-4177.
10. Johansen P., Men Y., Merkle H.P., Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm 2000 Jul 3, 50(1):129-146.
11. Waeckerle-Men Y., Groettrup M. PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev 2005, 57(3):475-482.
12. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
13. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.T., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767.
14. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
15. Shortman K., Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002, 2(3):151-161.
16. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
17. Tacken P.J., de Vries I., Torensma R., Figdor C.G. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007, 7(10):790-802.
18. Gogolak P., Rethi B., Hajas G., Rajnavolgyi E. Targeting dendritic cells for priming cellular immune responses. J Mol Recognit 2003, 16(5):299-317.
19. Wattendorf U., Coullerez G., Voros J., Textor M., Merkle H.P. Mannose-based molecular patterns on stealth microspheres for receptor-specific targeting of human antigen-presenting cells. Langmuir 2008, 24(20):11790-11802.
20. Yang L., Yang H., Rideout K., Cho T., Il Joo K., Ziegler L., et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008, 26(3):326-334.
21. Bonifaz L., Bonnyay D., Mahnke K., Rivera M., Nussenzweig M.C., Steinman R.M. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8(+) T cell tolerance. J Exp Med 2002, 196(12):1627-1638.
22. Sw Choe, Acharya A.P., Keselowsky B.G., Sorg B.S. Intravital microscopy imaging of macrophage localization to immunogenic particles and co-localized tissue oxygen saturation. Acta Biomater 2010, 6(9):3491-3498.
23. Cheong C., Choi J.H., Vitale L., He L.Z., Trumpfheller C., Bozzacco L., et al. Improved cellular and humoral immune responses in vivo following targeting of HIV gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 2010, 116(19):3828-3838.
24. Nchinda G., Kuroiwa J., Oks M., Trumpfheller C., Park C.G., Huang Y., et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008, 118(4):1427-1436.
25. Keselowsky B.G., Xia C.Q., Clare-Salzler M. Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes. Hum Vaccines 2011, 7(1):37-44.
26. Jiang W.P., Swiggard W.J., Heufler C., Peng M., Mirza A., Steinman R.M., et al. The receptor Dec-205 expressed by dendritic cells and thymic epithelial-cells is involved in antigen-processing. Nature 1995, 375(6527):151-155.
27. Wang B., Kuroiwa J.M., He L.Z., Charalambous A., Keler T., Steinman R.M. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci 2009, 1174:6-17.
28. Stern J.N., Keskin D.B., Kato Z., Waldner H., Schallenberg S., Anderson A., et al. Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. P Natl Acad Sci 2010, 107(40):17280-17285.
29. Yamazaki S., Dudziak D., Heidkamp G.F., Fiorese C., Bonito A.J., Inaba K., et al. CD8(+)CD205(+) splenic dendritic cells are specialized to induce Foxp3(+) regulatory T cells. J Immunol 2008, 181(10):6923-6933.
30. Ammon C., Meyer S.P., Schwarzfischer L., Krause S.W., Andreesen R., Kreutz M. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 2000, 100(3):364-369.
31. Berry J.D., Licea A., Popkov M., Cortez X., Fuller R., Elia M., et al. Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybrid Hybridomics 2003, 22(1):23-31.
32. Ihanus E., Uotila L.M., Toivanen A., Varis M., Gahmberg C.G. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4. Blood 2007, 109(2):802-810.
33. Bailly P., Tontti E., Hermand P., Cartron J.P., Gahmberg C.G. The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins. Eur J Immunol 1995, 25(12):3316-3320.
34. Ihanus E., Uotila L., Toivanen A., Stefanidakis M., Bailly P., Cartron J.P., et al. Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins. Eur J Biochem 2003, 270(8):1710-1723.
35. Messerschmidt S.K., Musyanovych A., Altvater M., Scheurich P., Pfizenmaier K., Landfester K., et al. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release 2009, 137(1):69-77.
36. Zaveri T.D., Dolgova N.V., Chu B.H., Lee J., Wong J., Lele T.P., et al. Contributions of surface topography and cytotoxicity to the macrophage response to zinc oxide nanorods. Biomaterials 2010, 31(11):2999-3007.
37. Li Y.P., Pei Y.Y., Zhang X.Y., Gu Z.H., Zhou Z.H., Yuan W.F., et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release 2001, 71(2):203-211.
38. Kiama S.G., Cochand L., Karlsson L., Nicod L.P., Gehr P. Evaluation of phagocytic activity in human monocyte-derived dendritic cells. J Aerosol Med: J Int Soc Aerosols Med 2001, 14(3):289-299.
39. Thiele L., Merkle H.P., Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res 2003, 20(2):221-228.
40. Phillips B., Nylander K., Harnaha J., Machen J., Lakomy R., Styche A., et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008, 57(6):1544-1555.
41. Hamdy S., Haddadi A., Hung R.W., Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011, 63(10-11):943-955.
42. Kempf M., Mandal B., Jilek S., Thiele L., Voros J., Textor M., et al. Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles. J Drug Target 2003, 11(1):11-18.
43. Acharya A.P., Dolgova N.V., Xia C.Q., Clare-Salzler M.J., Keselowsky B.G. Adhesive substrates modulate the activation and stimulatory capacity of non-obese diabetic mouse-derived dendritic cells. Acta Biomater 2011, 7(1):180-192.
44. Acharya A.P., Dolgova N.V., Moore N.M., Xia C.Q., Clare-Salzler M.J., Becker M.L., et al. The modulation of dendritic cell integrin binding and activation by RGD-peptide density gradient substrates. Biomaterials 2010, 31(29):7444-7454.
45. Acharya A.P., Dolgova N.V., Clare-Salzler M.J., Keselowsky B.G. Adhesive substrate-modulation of adaptive immune responses. Biomaterials 2008, 29(36):4736-4750.
46. Faham A., Altin J.G. Ag-bearing liposomes engrafted with peptides that interact with CD11c/CD18 induce potent Ag-specific and antitumor immunity. Int J Cancer 2011, 129(6):1391-1403.
47. Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S.I., Soares H., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199(6):815-824.
48. Birkholz K., Schwenkert M., Kellner C., Gross S., Fey G., Schuler-Thurner B., et al. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 2010, 116(13):2277-2285.
49. Bandyopadhyay A., Fine R.L., Demento S., Bockenstedt L.K., Fahmy T.M. The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 2011, 32(11):3094-3105.
50. Brandhonneur N., Chevanne F., Vie V., Frisch B., Primault R., Le Potier M.F., et al. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci 2009, 36(4-5):474-485.
51. Singh M., Chakrapani A., O'Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007, 6(5):797-808.
52. Mailender V., Landfester K. Interaction of nanoparticles with cells. Biomacromolecules 2009, 10(9):2379-2400.
53. Tan H., Huang D., Lao L., Gao C. RGD modified PLGA/gelatin microspheres as microcarriers for chondrocyte delivery. J Biomed Mater Res B 2009, 91B(1):228-238.
54. Lin S.X., Mallet W.G., Huang A.Y., Maxfield F.R. Endocytosed cation-independent mannose 6-phosphate receptor traffics via the endocytic recycling compartment en route to the trans-golgi network and a subpopulation of late endosomes. Mol Biol Cell 2004, 15(2):721-733.
55. Petrie T.A., Capadona J.R., Reyes C.D., Garcia A.J. Integrin specificity and enhanced cellular activities associated with surfaces presenting a recombinant fibronectin fragment compared to RGD supports. Biomaterials 2006, 27(31):5459-5470.
56. Kou P.M., Babensee J.E. Macrophage and dendritic cell phenotypic diversity in the context of biomaterials. J Biomed Mater Res A 2011, 96(1):239-260.
57. Hashimoto D., Miller J., Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity 2011, 35(3):323-335.
58. Fredriksen Br N., Grip J. PLGA/PLA micro- and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.). Vaccine 2012, 30(3):656-667.
59. Jefford M., Schnurr M., Toy T., Masterman K.A., Shin A., Beecroft T., et al. Functional comparison of DCs generated in vivo with Flt3 ligand or in vitro from blood monocytes: differential regulation of function by specific classes of physiologic stimuli. Blood 2003, 102(5):1753-1763.
60. Inaba K., Swiggard W.J., Inaba M., Meltzer J., Mirza A., Sasagawa T., et al. Tissue distribution of the Dec-205 protein that is detected by the monoclonal-antibody Nldc-145.1. Expression on dendritic cells and other subsets of mouse leukocytes. Cell Immunol 1995, 163(1):148-156.
61. Guo M., Gong S., Maric S., Misulovin Z., Pack M., Mahnke K., et al. A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. Hum Immunol 2000, 61(8):729-738.